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Abstract. Uncertainty exists regarding the necessity of continu-
ing triple therapy consisting of mycophenolate mofetil (MMF),
cyclosporine (CsA), and prednisone (Pred) after kidney trans-
plantation (RTx). At 6 mo after RTx, 212 patients were ran-
domized to stop CsA (n  63), stop Pred (n  76), or continue
triple drug therapy (n  73). The MMF dose was 1000 mg
twice daily, target CsA trough levels were 150 ng/ml, and Pred
dose was 0.10 mg/kg per d. Follow-up was until 24 mo after
RTx. Biopsy-proven acute rejection occurred in 14 (22%) of 63
patients after CsA withdrawal compared with 3 (4%) of 76 in
the Pred withdrawal group (P 0.001) and 1 (1.4%) of 73 in the
control group (P 0.0001). Biopsy-proven chronic rejection was
present in one patient in the control group, in nine patients after
CsA withdrawal (P  0.006 versus control group); and in four
patients after discontinuation of Pred (NS). Graft loss occurred in
two versus one patient after CsA or Pred withdrawal, respectively,
and in two patients in the control group (NS). Patients who
successfully withdrew CsA had a significantly lower serum cre-
atinine during follow-up. Pred withdrawal resulted in a reduction
in mean arterial pressure, and the total cholesterol/HDL ratio
increased. In conclusion, rapid CsA withdrawal at 6 mo after RTx
results in a significantly increased incidence of biopsy-proven
acute and chronic rejection. Pred withdrawal was safe and resulted
in a reduction in mean arterial pressure. However, patient and
graft survival and renal function 2 yr after RTx were not different
among groups.
The addition of mycophenolate mofetil (MMF) to cyclosporine
(CsA) and prednisone (Pred) results in a decrease in the inci-
dence of acute rejections during the first 6 mo after kidney
transplantation (1–4). Whether or not MMF has an inhibitory
effect on the development of chronic rejection, either resulting
from fewer early acute rejection episodes or as a specific
MMF-related effect, is still a matter of debate (4,5,6). Mean-
while, the possibility of over-immunosuppression associated
with long-term continuation of triple drug therapy is a matter of
concern. Furthermore, both CsA and Pred have specific drug-
related adverse effects on cardiovascular risk factors that may
negatively influence long-term outcome. Therefore, we per-
formed a randomized, prospective multicenter study to com-
pare the effect of withdrawing CsA or Pred from a triple drug
regimen consisting of MMF, CsA, and Pred at 6 mo after renal
transplantation in stable renal transplant patients, with patients
continuing triple drug therapy as controls.
Materials and Methods
Between January 1997 and January 1999, 313 patients undergoing
kidney transplantation in the university hospitals of Rotterdam,
Utrecht, and Nijmegen in the Netherlands entered a study that eval-
uated the cyclosporine-sparing effect of MMF in the first 6 mo after
transplantation, the results of which have been published in this
journal (7). After completion of 6 mo of follow-up, 212 (68%) of 313
of these patients were enrolled and randomized to participate in this
subsequent multicenter, open-label trial of CsA or Pred withdrawal.
During the first 6 mo after transplantation, 22 patients had lost their
graft and 8 patients died with a functioning graft. Excluded from
randomization were patients with two or more acute rejections during
the first 6 mo after transplantation (n  15), patients with biopsy-
proven chronic vascular rejection (n  3), patients with proteinuria of
more than 3 g/d (n  2), patients with an unstable graft function (n 
9), and patients not treated with triple drug therapy (MMF, CsA, Pred)
at the time of randomization (n  29). At the time of randomization,
seven patients refused to participate in the study. In five cases, the
treating physician decided not to ask the patient for participation
because of multiple HLA-mismatches, previous severe acute rejec-
tion, or liver function disturbances. One patient was lost to follow-up
before randomization. The study design was approved by the institu-
tional review boards of the three participating hospitals, and written
informed consent was obtained from all participants.
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Randomization Procedure
Patients were randomly assigned to one of the three treatment
groups in a 1:1:1 ratio, with stratification for cadaveric/living related
transplant, for center, and for the number of acute rejections during
the first 6 mo after transplantation. Randomization was carried out by
opening a sealed envelope with the lowest available study number.
Immunosuppression
Patients were treated with 1000 mg of MMF twice daily, 0.1 mg/kg
Pred per day, and CsA targeted at trough levels between 125 and 175
ng/ml (from 3 mo after transplantation). The microemulsion formu-
lation of CsA (Neoral; Novartis, East Hanover, NJ) was used in all
patients. No induction antibody therapy was used. Dose reduction or
interruption of MMF treatment was allowed in cases of leukocytope-
nia or anemia, primary cytomegalovirus (CMV) infection, or severe
gastrointestinal side effects. In the patients randomized for discontin-
uation of CsA, the CsA dose was reduced by 50% for 2 wk before
complete cessation while increasing the prednisone dose to 0.15
mg/kg per d and continuing 2 g of MMF daily. In nine patients, the
CsA dose was reduced by 25% every 3 wk before complete discon-
tinuation. The patients randomized for discontinuation of Pred were
tapered off the Pred to 0 mg in 10 wk (according to protocol) while
continuing CsA and MMF in unchanged dosages.
Acute rejections were treated primarily with 1000 mg of intrave-
nous methylprednisolone during three consecutive days. Steroid-re-
sistant rejections were treated with anti–T cell therapy, either rabbit
polyclonal antithymocyte globulin (ATG) or a mouse anti-CD3 mono-
clonal antibody (WT32) (8). If patients in one of the withdrawal
groups needed anti–T cell rejection treatment, therapy with CsA or
Pred was reinstituted. CMV prophylaxis with ganciclovir or CMV
hyperimmune globulin was prescribed during anti–T cell therapy in
patients at risk for CMV disease (donor and/or recipient seropositive).
Assessments
At baseline, the medical history, physical examination, routine
laboratory tests, lipid profile, and histocompatibility data were ob-
tained. Vital signs, body weight, and the results of routine laboratory
measurements were recorded every month. Data on rejection epi-
sodes, CsA nephrotoxicity, concomitant medication, adverse events,
and infections were gathered throughout the entire study period. CsA
whole blood levels were measured with a monoclonal antibody
against the CsA parent molecule, using the fluorescence-polarization
immunoassay on an Abbott TDx analyser (Abbott Laboratories, North
Chicago, IL) or with an enzyme-multiplied immunoassay on a CO-
BAS-MIRA analyser (Dade-Behring, San Jose´, CA). A biopsy was
performed in cases of deteriorating graft function without an obvious
prerenal or postrenal cause, suspected CsA nephrotoxicity, or in cases
of increasing proteinuria. No protocol biopsies were performed.
Biopsies were examined by the local pathologist and were classi-
fied according to the Banff 1993 biopsy scoring system (grade 1, mild
rejection; grade 2, moderate rejection; grade 3, severe rejection) (9).
Patients were presumed to have acute rejection if antirejection treat-
ment without prior biopsy resulted in a decrease in serum creatinine
without an obvious prerenal or postrenal cause. The creatinine clear-
ance was estimated according to the Cockcroft and Gault method (10).
Infections were classified by using the Centers for Disease Control
definitions for nosocomial infections (11).
Statistical Analyses
Primary end points for analysis were first biopsy-proven acute or
chronic rejection between 6 mo (i.e., time of randomization) and 24 mo
after transplantation. Secondary end points were patient and graft sur-
vival, renal function at 1 and 2 yr after transplantation, the incidence of
infections and malignancies, and changes in BP and lipid metabolism.
Data were analyzed on an intention-to-treat basis. For comparisons
of numerical data within groups, a paired nonparametric test was
performed (Wilcoxon signed rank test). When appropriate, a t test was
performed. For comparisons of numerical data among different
groups, a nonparametric ANOVA was performed (Kruskal-Wallis
test). Comparison of time to first biopsy-proven acute rejection was
performed using the Kaplan-Meier procedure with log rank testing.
Multiple logistic regression analysis was performed to determine
risk-factors associated with the occurrence of acute rejection after
randomization. The following variables were entered: gender, age,
panel reactive antibodies (PRA), number of transplantation, postmor-
tal or living donor, number of HLA mismatches, serum creatinine at
randomization, biopsy-proven rejection during the first 6 mo, and
randomization group.
A second analysis, on treatment, was performed for renal function
at 1 and 2 yr after transplantation and changes in lipid metabolism at
2 yr after transplantation. For renal function, patients with or without
calcineurin inhibitors were compared; comparison among groups was
performed with a Mann-Whitney test, and a repeated measurements
analysis (general linear model) was performed to exclude a putative
influence of a baseline difference between the two groups. Compar-
ison of numerical data for changes in lipid metabolism was performed
with nonparametric ANOVA (Kruskal-Wallis test).
Results are given as median with range or as mean with SD, unless
stated otherwise. P  0.05 was considered statistically significant; all
tests were two-sided. Calculations were performed using the software
programs, SPSS 8.0 for Windows (SPSS Inc., Chicago, IL) and
Graphpad Instat, version 3.00 for Windows (Graphpad Software Inc.,
San Diego, CA).
Results
Six months after transplantation, 63 patients were random-
ized for discontinuation of CsA, 76 patients for discontinuation
of prednisone, and 73 patients for continuation of triple ther-
apy. Baseline characteristics are summarized in Table 1; no
statistically significant differences existed among the groups.
There were no black patients in this study cohort.
Biopsies
During the study period, a total of 47 renal biopsies were
performed: 33 first, 13 second, and 1 third biopsy. In the CsA
withdrawal group, there were 19 first, 9 second, and 1 third
biopsies. In the Pred withdrawal group, there were 9 first and
3 second biopsies. In the control group, there were 5 first and
1 second biopsies.
Acute Rejections
In Table 2, all first biopsy-proven acute rejections after
randomization are shown. The incidence of acute rejection was
significantly higher after withdrawal of CsA than after with-
drawal of steroids or during continuation of triple therapy. As
depicted in Figure 1, most rejections occurred within 3 mo
after conversion from triple to double therapy. The median
time from randomization to first biopsy-proven acute rejection
was 74 d (26 to 244 d) and 72 d (22 to 211 d) for the CsA and
Pred withdrawal groups, respectively.
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In a multiple logistic regression model, the only variable that
was significantly related to the occurrence of biopsy-proven acute
rejection after randomization was the group for which patients
were randomized (P  0.0003). Neither number of HLA mis-
matches nor rejection during the first 6 mo were predictive of
acute rejection after CsA or Pred withdrawal at 6 mo.
In the CsA withdrawal group, there were two patients with a
presumed acute rejection. No biopsy was performed in these two
patients, but a course of methylprednisolone resulted in recovery
of the serum creatinine to initial values. Of the nine patients who
tapered their CsA dosage during a 9-wk period, only one patient
developed a biopsy-proven acute rejection. However, this was not
significantly different from the rejection incidence (13 of 54) in
patients who discontinued CsA in 2 wk. A second biopsy-proven
acute rejection occurred in five patients in the CsA withdrawal
group; in three of five cases, this second acute rejection was
steroid-resistant. One patient in the CsA withdrawal group was
treated with methylprednisolone for a presumed second rejection
(not biopsy-proven). In the Pred withdrawal group, one patient
developed a second biopsy-proven acute rejection that responded
to treatment with methylprednisolone. There were no presumed
rejections in this group.
The only patient randomized for triple drug therapy who
developed an acute rejection had stopped MMF 9 d earlier
because of side effects.
Chronic Rejections and CsA Nephrotoxicity
In the CsA withdrawal group, nine patients had a biopsy
showing histologic changes compatible with chronic rejection.
In five of these patients, there were no concomitant signs of
acute rejection. The incidence of biopsy-proven chronic rejec-
tion in the CsA withdrawal group (9 of 63) was significantly
higher than in the control group (1 of 73; P  0.006). Four
patients in the Pred withdrawal group had histologic evidence
Table 1. Baseline characteristics at time of randomization, 6 mo after kidney transplantation. There are no statistically
significant differences among the three groups
Parameter MMF/Pred MMF/CsA MMF/CsA/Pred
n patients 63 76 73
Age (yr) 52 (20 to 72) 52 (19 to 68) 51 (19 to 70)
Female/male 21/42 24/52 27/46
First/second graft 57/6 68/8 64/9
Postmortal/living donor 48/15 58/18 54/19
HLA mismatchesb
HLA-A 0.78 0.66 0.87 0.52 0.68 0.53
HLA-B 0.90 0.58 1.0 0.65 0.66 0.58
HLA-DR 0.71 0.66 0.95 0.60 0.67 0.53
PRA 10%
historical (%) 43 39 48
recent (%) 17 13 23
Acute rejection 6 mo (biopsy-proven) 10 11 8
CsA
dose (mg/d)b 283 102 288 85 288 84
level (ng/ml)b 160 39 158 40 158 42
a MMF, mycophenolate mofetil; CsA, cyclosporine; Pred, prednisone.
b Mean  SD.
Table 2. First biopsy-proven acute rejections, according to the BANFF 1993 classification, and anti-rejection therapy needed
per patient per group
Parameter MMF/Pred MMF/CsA MMF/CsA/Pred
n patients 63 76 73
Acute rejection 14ab 3b 1a
BANFF I 5 2 1
BANFF II 9 1 0
Anti-rejection therapy
methylprednisolone 13 4 1
anti–T cell antibodies 6 2 0
a Pairwise comparison among groups, P  0.0001.
b Pairwise comparison among groups, P  0.0014.
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of chronic rejection, and two of these patients had concomitant
acute rejection. When comparing the incidence of chronic
rejection in biopsies only, there was no statistically significant
difference among all groups; 9 of 33 versus 4 of 19 versus 1 of
9 for the CsA and Pred withdrawal and control groups,
respectively.
Histologic changes compatible with CsA nephrotoxicity
were present in one patient in the CsA withdrawal group, in
three patients in the Pred withdrawal group, and in four pa-
tients in the control group.
Graft Failure, Patient Death, and Treatment Failure
Graft failure without patient death occurred in 2 of 63
patients in the CsA withdrawal group. The cause of graft
failure was chronic rejection in both patients. Graft failure,
without patient death, occurred once in the Pred withdrawal
group because of chronic rejection. In 2 patients in the control
group, immunosuppressive medication was stopped com-
pletely, followed by graft failure. The reasons for cessation of
immunosuppressive medication were severe myositis and post-
transplant lymphoma (the latter patient died 2 mo later). Patient
death with functioning graft only occurred in the groups con-
tinuing CsA (3 of 149). In one case, the cause of death was
documented myocardial infarction; two patients were found
dead at home, presumably as a result of fatal myocardial
infarction (Table 3). Treatment failure, defined as changes in
immunosuppressive therapy or reinstitution of the discontinued
drug, resulted from various causes (Table 4). In the CsA
withdrawal group, calcineurin inhibitors were mostly restarted
after acute rejection episodes requiring anti–T cell therapy
(protocol driven). Pred withdrawal was uneventful for almost
all patients.
Graft Function, Proteinuria, and BP
When comparing renal function among the three groups
(intention-to-treat analysis), there were no statistically signifi-
cant differences in serum creatinine or creatinine clearance
among the three groups at 6, 12, and 24 mo after transplanta-
tion (Table 5). In addition, there were no significant changes in
serum creatinine or creatinine clearance within the three groups
during follow-up (intention-to-treat analysis).
However, 24% of patients in the CsA withdrawal group used
calcineurin inhibitors at 12 and 24 mo after transplantation,
which might negate a positive effect of CsA withdrawal on
renal function. When comparing renal function in patients with
or without calcineurin inhibitors (on-treatment analysis), a
statistically significant difference in serum creatinine at 12 and
24 mo after transplantation was present. The median serum
creatinine at 6, 12, and 24 mo for patients with or without
calcineurin inhibitors were: 135 mol/L (61 to 411) versus 125
mol/L (65 to 267), NS; 135 mol/L (59 to 368) versus 119
mol/L (68 to 226), P  0.01; and 144 mol/L (64 to 295)
versus 124 mol/L (72 to 332), P  0.001, respectively. The
repeated measurements analysis on renal function in time dem-
onstrated only a statistically significant difference between
patients with or without calcineurin inhibitors (P  0.001).
At randomization, proteinuria (0.5 g/d) was present in
18% of patients in the CsA withdrawal group, 16% in the Pred
withdrawal group, and 15% in the control group. After 18 mo
of follow-up, these percentages were 18% in the CsA with-
drawal group compared with 20% in the Pred withdrawal
group and 12% in the control group (no significant differences
or changes).
In Table 6, the results regarding BP are shown. Only in the
Pred withdrawal group was a statistically significant reduction
Figure 1. Kaplan-Meier survival curve that demonstrates the time to
first biopsy-proven acute rejection for all groups from 6 mo after
transplantation during a follow-up period of 18 mo. MMF, mycophe-
nolate mofetil; CsA, cyclosporine; Pred, prednisone.
Table 3. Patient and graft survival after conversion per group after 1.5-yr follow-up. Incidence of malignancies per groupa
Parameter MMF/Pred MMF/CsA MMF/CsA/Pred
n patients 63 76 73
Graft failure 2 1 2
Patient death 0 2 2
Malignancies 0 1 2
PTLD 0 0 1
skin (non-melanoma) 0 1 1
a PTLD, posttransplantation lymphoproliferative disorder.
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in mean arterial pressure observed without a concomitant in-
crease in the number of antihypertensive drugs.
Infections and Malignancies
The incidence of infections did not differ among groups: 1.4
infections/patient in the CsA withdrawal group, 1.2 infections/
patient in the Pred withdrawal group, and 1.3 infections/patient in
the control group. There also was no difference in the distribution
or type of infections among the three groups (Table 7).
Only three malignancies occurred during the 18-mo fol-
low-up (Table 3). One posttransplant lymphoma was present in
the control group. This patient was treated with r-ATG in the
first 6 mo after transplantation because of an acute rejection
episode. The other two malignancies were skin carcinomas
(non-melanoma). One of these patients had had a previous
transplantation.
Lipid Metabolism
To appreciate the immediate as well as the chronic effects of
withdrawal of CsA and Pred on lipid metabolism, values at the
Table 4. Treatment failure per group during 18 mo of follow-up after randomizationa
Parameter MMF/Pred MMF/CsA MMF/CsA/Pred
n patients 63 76 73
Medication never stopped 1 1 NA
Medication restarted 14c 4c NA
Medication stopped
MMF 3 0 5
CsA NA 0 1
Pred 0 NA 0
all 0 0 1
Total n 18b 5b 7
a NA, not applicable.
b Pairwise comparison among groups, P  0.03.
c Pairwise comparison among groups, P  0.004.
Table 5. Serum creatinine and creatinine clearance (Cockcroft-Gault) for all groups (median and range) from time of
randomization (month 6) and 12 and 24 mo after transplantation
Group Month 6 Month 12 Month 24
MMF/Pred
creatinine (mol/L) 118 (65 to 267) 117 (68 to 228) 123 (72 to 332)
creatinine clearance (ml/min) 62 (30 to 100) 66 (31 to 100) 64 (18 to 104)
MMF/CsA
creatinine (mol/L) 130 (61 to 242) 137 (70 to 274) 137 (65 to 293)
creatinine clearance (ml/min) 61 (31 to 115) 58 (30 to 117) 58 (28 to 103)
MMF/CsA/Pred
reatinine (mol/L) 123 (65 to 411) 124 (59 to 368) 125 (64 to 276)
reatinine clearance (ml/min) 65 (20 to 156) 63 (22 to 121) 65 (34 to 116)
Table 6. BP and number of antihypertensive drugs needed at time of randomization and after 1.5-yr follow-up after
conversion (mean  SD.)
Parameter Month 6 Month 24 P
Mean arterial pressure (mmHg)
MMF/Pred 105 1.4 101 1.5 0.037
MMF/CsA 104 1.4 101 1.4 0.017
MMF/CsA/Pred 104 1.3 107 2.9 NS
Antihypertensive drugs (n)
MMF/Pred 1.2 0.12 1.5 0.14 0.027
MMF/CsA 1.3 0.13 1.4 0.13 NS
MMF/CsA/Pred 1.3 0.11 1.7 0.13 0.001
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time of randomization are compared with those obtained at 3
mo and at 18 mo after randomization (Table 8). The with-
drawal of either CsA or Pred was followed by a rapid fall in
total cholesterol levels. However, discontinuation of Pred also
resulted in a transient significant decrease in HDL-cholesterol.
Consequently, there was an unbeneficial rise in the total/HDL
cholesterol ratio in this group 3 mo after randomization.
Among the three groups, there was an equally distributed
percentage of patients treated with cholesterol-lowering drugs
(mostly statins).
The on-treatment analysis for all three groups revealed a
statistically significant difference in the total cholesterol at 24
mo for the Pred withdrawal group compared with all three
groups at the time of randomization: 5.65 mmol/L compared
with 6.5, 6.6, and 6.6 mmol/L, respectively. There were no
statistical differences in the ratio of total/HDL cholesterol at 6
mo or 24 mo after transplantation among the three groups.
Discussion
Treatment with the combination of MMF, CsA, and Pred has
decreased the incidence of acute rejection to 20% in the first
half-year after kidney transplantation (1–4). Long-term graft
Table 7. Number of infections for all groups during follow-up (18 mo), after randomisation
Infection MMF/Pred MMF/CsA MMF/CsA/Pred P
n patients 63 76 73
Viral infections NS
herpes simplex 5 5 8
herpes zoster 2 3 0
cytomegalovirus 4 1 2
Opportunistic infections NS
candida stomatitis 3 3 1
oesofagitis 0 1 1
Bacterial infections NS
urinary tract 36 31 33
pneumonia/bronchitis 3/2 3/8 5/10
upper respiratory tract 13 16 16
skin 7 6 3
gastrointestinal tract 4 3 3
other 1 1 4
Sepsis 3 0 2 NS
Culture-negative infection 3 12 10 NS
Total 85 93 98 NS
Table 8. Effect of withdrawal of CsA or Pred, compared with continuation of MMF/CsA/Pred therapy, on lipid metabolism
at 6, 9, and 24 mo (mean  SD)
Group Month 6 Month 9 Month 24
MMF/Pred
total cholesterol (mmol/L) 6.63 1.81 6.04 1.64 6.16 1.37
ratio total/HDL 5.8 2.6 5.3  2.7 4.9 1.7
triglycerides (mmol/L) 2.56 1.98 2.30 2.66 2.18 1.90a
cholesterol-lowering medication (%) 0 2 16
MMF/CsA
total cholesterol (mmol/L) 6.69 1.42 6.1 1.24 5.69 1.22
Ratio total/HDL 6.0 2.4 6.6  2.8 5.7 2.5
triglycerides (mmol/L) 2.59 1.31 2.62 1.39 2.8 1.29a
cholesterol-lowering medication (%) 0 5 18
MMF/CsA/Pred
total cholesterol (mmol/L) 6.66 1.62 6.61 1.54 6.19 1.28
ratio total/HDL 6.0 2.4 5.7  2.2 5.1 1.9
triglycerides (mmol/L) 2.62 2.12 2.33 1.13 2.23 1.22
cholesterol-lowering medication (%) 6 4 15
a ANOVA (Kruskal-Wallis test) for comparison between groups P  0.05
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survival, excluding patient death as a cause of graft failure, is
primarily influenced by the occurrence of chronic rejection
with subsequent development of renal failure (12,13). The
reduced survival of kidney transplantation patients is largely a
result of the high risk of cardiovascular disease and malignan-
cies in this population (14). Unwanted side effects of both CsA
and Pred, such as hyperlipidemia and hypertension, contribute
to the increased risk for developing cardiovascular disease
(15,16). MMF has no adverse effect on cardiovascular risk
factors. Therefore, discontinuation of either CsA or Pred might
positively influence the cardiovascular risk profile, albeit with
a small risk of acute rejection or even graft loss (17–19). The
3-yr follow-up from the European MMF study indicated a
modest but not statistically significant effect of the addition of
MMF on graft survival, which was attributed solely to the
lower incidence of acute rejection (5). Data from the US renal
transplant scientific registry demonstrated a reduction in the
occurrence of chronic rejection for patients treated with MMF,
independent of acute rejection, compared with patients treated
with azathioprine in combination with calcineurin-inhibitors
with or without Pred (20). As long as data demonstrating the
need for continuation of full-dose triple drug therapy to achieve
superior long-term patient and graft survival are not available,
the risks of over-immunosuppression favor discontinuation of
one or more drugs.
In our study, the patients discontinuing CsA had the highest
incidence of acute rejection (22%), and these acute rejections
were severe (grade II) in 9 of 14 cases. Severe acute vascular
rejections are known to have a poor prognosis for long-term
graft survival (21). Our data are in variance with the results of
a recent meta-analysis by Kasiske et al. (22), which reported a
risk for acute rejection after CsA withdrawal of 11% without
increased graft loss during long-term follow-up (5 yr). A
possible contributing factor to the increased incidence of bi-
opsy-proven rejections in our study might be the rapid CsA
withdrawal. Although no significant difference was observed
in our study between patients with two different withdrawal-
schedules, lower rejection rates have been described with a
longer period of stepwise CsA withdrawal (18,23). Despite the
higher incidence of acute rejections after discontinuation of
CsA, no detrimental effect on creatinine clearance was noted.
This might be caused by a simultaneously occurring disappear-
ance of CsA-associated nephrotoxicity during the first 3 mo
after withdrawing CsA. The on-treatment analysis of patients
with or without calcineurin inhibitors confirmed the positive
effect of CsA withdrawal on renal function.
Pred withdrawal did not increase the incidence of acute
rejection episodes compared with the control group. Similar
results were previously reported by Grinyo´ et al. (24), although
the risk for acute rejection after Pred withdrawal was 14% in a
meta-analysis (22). However, the continuation of CsA and
MMF was not used as baseline immunosuppression after Pred
withdrawal in most studies included in this meta-analysis.
Two multicenter trials of Pred withdrawal from 3 mo after
kidney transplantation in patients maintained on CsA and
MMF demonstrated an incidence of acute rejection at 1 yr after
transplantation of 30.8% (US trial) and 25% (European trial),
respectively (17,25). The US trial had the highest incidence of
acute rejection in African Americans (39.6%) compared with
16% in non–African Americans (25). Possible explanations for
the lower incidence of acute rejections between our study and
the US and the European trials might be the time of Pred
withdrawal after transplantation (6 mo versus 3 mo) and how
rapidly Pred was withdrawn (10 wk versus 8 wk). No African
Americans were present in our study. No induction therapy
was given in our study, in contrast to 27% of patients in the US
and in the European trial. However, no protective effect of
induction therapy could be demonstrated in the US trial (un-
derpowered test). The European trial demonstrated an inci-
dence of biopsy-proven acute rejection of 16% compared with
27% in the withdrawal patients with or without induction
therapy, respectively, a difference that was not statistically
significant (17).
There appears to be an increased incidence of chronic rejec-
tion in the CsA withdrawal group compared with the other
groups. It must be stressed however that there was a substan-
tially higher number of biopsies performed in the CsA with-
drawal group and the indication for the biopsies was the
suspicion of an acute rather than a chronic rejection in most
cases.
Although no significant differences exist in patient survival
among groups, the causes of death were cardiovascular in
patients continuing CsA. In the Pred withdrawal group, there
was a significant decrease in mean arterial pressure without the
need for more medication; patients continuing triple therapy
required more antihypertensive medication to prevent a rise in
mean arterial pressure. This positive effect of Pred withdrawal
on BP has previously been reported for patients withdrawing
prednisone at 3 mo or 1 yr after kidney transplantation (26,27).
Long-term follow-up data (5 yr) of patients withdrawing
CsA from 3 mo after transplantation showed less cardiovascu-
lar deaths, less hypertension, and better renal function com-
pared with patients continuing CsA (28). In our study, with-
drawal of CsA was also followed by a decrease in mean arterial
pressure, but this was achieved by an increase in antihyperten-
sive medication. As a consequence of the intention-to-treat
analysis, the effects of discontinuation of CsA are obscured by
the proportion of patients in whom this drug was reintroduced
(29%). In conversion studies with patients switching from CsA
to azathioprine or MMF, beneficial effects on BP and lipid
profile were also noted (18,26,29).
Three months after withdrawing either CsA or Pred, a sub-
stantial decrease in total cholesterol was observed. However, a
more favorable cardiovascular risk-profile, reflected by a lower
total/HDL cholesterol ratio, was only present in the CsA with-
drawal group at 3-mo follow-up. There were no statistically
significant differences in lipid parameters among the three
groups at the end of follow-up. This may be due to the fact that
15% of the patients in all groups used cholesterol-lowering
drugs. It should furthermore be noted that 77% of patients used
calcineurin inhibitors at that time. On-treatment analysis of
changes in the total cholesterol from randomization until the
end of follow-up only demonstrated a beneficial effect for
patients withdrawing Pred.
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There was no evidence of over-immunosuppression or an
increased cardiovascular risk in these patients, although the
follow-up period of 18 mo does not allow firm conclusions
regarding these issues.
Do the results of our study help decide which immunosup-
pressive regimen is preferred as maintenance therapy? The
relatively short follow-up of 18 mo potentially underestimates
the benefits of improving the cardiovascular risk-profile in the
CsA and Pred withdrawal groups. Likewise, CsA-induced in-
terstitial fibrosis with subsequent loss of renal function may
only become apparent after prolonged use of this drug. Nev-
ertheless, the increased number of acute rejections in the CsA
withdrawal group could deter clinicians from following this
strategy. There is a clear need for screening tests that identify
those patients at increased risk for acute rejection after tapering
of immunosuppressive medication. We recently showed that
measurement of the frequency of precursor cytotoxic T lym-
phocytes in peripheral blood allows the identification of a
subgroup of patients in whom tapering of immunosuppression
was safe (30,31). In the future, such tests may aid physicians
not only in the selection of patients in whom drug treatment
can be tapered but also to know which degree the level of
immunosuppression can be reduced in the individual patient.
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